Watchlist Price Alert

Entrada Therapeutics Inc. (TRDA)

NASDAQ: TRDA · Real-Time Price · USD

7.99

-0.71 (-8.16%)

At close: May 14, 2025, 3:59 PM

7.97

-0.25%

After-hours: May 14, 2025, 04:20 PM EDT

-8.16% (1D)

Bid	7.8
Market Cap	303.25M
Revenue (ttm)	172.22M
Net Income (ttm)	24.78M
EPS (ttm)	0.58
PE Ratio (ttm)	13.78
Forward PE	-2.7
Analyst	Buy

Ask	8.75
Volume	118,801
Avg. Volume (20D)	139,751
Open	8.70
Previous Close	8.70
Day's Range	7.98 - 8.75
52-Week Range	7.10 - 21.79
Beta	0.03

About TRDA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TRDA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TRDA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Entrada Therapeutics has released their quartely earnings on May 8, 2025:

Revenue of $20.56M exceeds estimates by $8.61M, with -65.23% YoY decline.

EPS of -0.42 exceeds estimates by 0.30, with -161.76% YoY decline.

Why Price Moved

9 months ago

+11.26%

Entrada Therapeutics shares are trading higher. Th... Unlock content with Pro Subscription

News

6 days ago · zacks.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago.

2 weeks ago · zacks.com

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a yea...

2 months ago · seekingalpha.com

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 milli...